<DOC>
	<DOCNO>NCT02394951</DOCNO>
	<brief_summary>The investigator seek investigate certain patient characteristic would predict response currently approve analgesic , pregabalin , patient chronic pain due nerve damage cause chemotherapy . Patients painful condition , call chemotherapy-induced peripheral neuropathy ( CIPN ) current recent history chemotherapy particular chemotherapy agent call taxanes oxaliplatin . The investigator recruit potential subject Siteman Cancer Center Washington University Pain Management Center . Those patient meet inclusion satisfy exclusion criterion enrol . Subjects undergo mechanical thermal sensitivity test extremity , provide quality life information complete questionnaire receive pregabalin follow placebo , placebo follow pregabalin [ crossover design ] order ass well sensory test predict analgesic effect pregabalin ( compare placebo ) .</brief_summary>
	<brief_title>Investigation Somatosensory Predictors Response Pregabalin Painful Chemotherapy-induced Peripheral Neuropathy ( CIPN )</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>1 . Age &gt; 18 2 . Distal symmetric pain distribution ( foot , without pain hand ) . 3 . The pain appear 12 week treatment oxaliplatin , paclitaxel , docetaxel combination . 4 . Score 4 DN4 ( Douleur Neuropathique 4 ) neuropathic pain questionnaire 5 . Pain duration &gt; 2 month . 6 . Patient report average daily pain intensity last week &gt; 3 010 Numerical Rating Scale ( NRS ) . 7 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . 8 . Able willing sign IRBapproved write informed consent . 1 . Hypersensitivity pregabalin . 2 . Current treatment pregabalin . 3 . Current treatment vinca alkaloid ( e.g . vincristine , vinblastine ) , CIPN may associate previous treatment vinca alkaloid . 4 . History diabetes mellitus neurological disorder previous sign distal symmetric polyneuropathy . 5 . Moderate severe renal failure ( Creatinine clearance &lt; 30mL/min , CockcroftGault formula ) . 6 . ALT ( alanine aminotransferase ) AST ( aspartate aminotransferase ) &gt; 3 time upper limit normal . 7 . Planned surgery radiation treatment within 10 week follow study inclusion . 8 . Inability complete pain selfreport . 9 . Pregnancy lactation 10 . Patients seizure disorder treat anticonvulsant 11 . Current participation trial another investigational agent . 12 . Concomitant medication follow : Subjects treat gabapentin anticonvulsant neuropathic pain require taper medication discontinue least 2 week prior study initiation . Patients antidepressant treatment pain depression ( TCAs , SSRI , SNRIs etc . allow continue medication provide stable dose least 4 week study initiation . No dose regimen change antidepressant allow study period . Patients aroundthe clock opioid treatment ( include tramadol ) allow continue medication provide stable dose least 4 week study initiation . The maximum allow dose opioid equivalent 60mg oral morphine sulphate . Patients higher dos require taper opioid dose maximum 60mg oral morphine equivalent , continue stable dose 4 week enrollment study . Shortacting opioids painful CIPN treatment allow . Treatment nonsteroidal antiinflammatory drug ( NSAIDs ) discontinue least 2 week study initiation . However , lowdose aspirin ( â‰¤325mg/day ) allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>chemotherapy</keyword>
</DOC>